Treatment of type 1 diabetes before and after expression of predisposition markers

Abstract

The present invention relates generally to the use of compounds, compositions, combinations, kits, and methods for the effective endocytic presentation of immunosuppressive factors for the down regulation of diabetogenic T cells for the treatment of type 1 diabetes.

1 . An immunoglobulin-polypeptide chimera comprising an immunoglobulin having a CDR3 region, wherein at least one diabetogenic epitope comprising a polypeptide having amino acid sequence of SEQ ID No: 3 is inserted within the CDR3 region. 
     
     
         2 . The chimera of  claim 1  wherein the immunoglobulin is aggregated. 
     
     
         3 . The chimera of  claim 1  wherein the immunoglobulin comprises IgG. 
     
     
         4 . The chimera of  claim 3  wherein said IgG is human IgG or humanized IgG. 
     
     
         5 . The chimera of  claim 1  wherein the at least one diabetogenic epitope replaces a D segment within said CDR3 region. 
     
     
         6 . A pharmaceutical composition comprising a chimera according to  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         7 . The composition of  claim 6  wherein the composition is formulated for intravenous delivery.